Once-weekly administration of high-dosage etanercept in patients with plaque psoriasis: Results of a pilot experience (power study)

International Journal of Immunopathology and Pharmacology

Volumn 19, Issue 1, 2006, Pages 225-229

  Cassano, N ^a   Loconsole, F ^a   Galluccio, A ^b   Miracapillo, A ^a   Pezza, M ^b   Vena, G A ^a  

^a UNIVERSITY OF BARI   (Italy)

^b Unit of Dermatology   (Italy)

Author keywords

Dosing regimen; Etanercept; Plaque psoriasis; Treatment

Indexed keywords

ETANERCEPT;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; PILOT STUDY; PRIORITY JOURNAL; PRURITUS; PSORIASIS VULGARIS; QUALITY OF LIFE; SCORING SYSTEM; VISUAL ANALOG SCALE;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PILOT PROJECTS; PSORIASIS; QUALITY OF LIFE; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 33646229093     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. No Authors listed. 2005. Enbrel®. Package insert.
2. Fredriksson T. and U. Pettersson. 1978. Severe psoriasis: Oral therapy with a new retinoid. Dermatologica 157:238.
3. Finlay A.Y. and G.K. Khan. 1994. Dermatology Life Quality Index (DLQI)- a simple practical measure for routine clinical use. Clin. Exp. Dermatol. 19:210.
4. Mease P.J., B.S. Goffe, J. Metz, A. VanderStoep, B. Finck and D.J. Burge. 2000. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356:385.
5. Leonardi C.L., J.L. Powers, R.T. Matheson, B.S. Goffe, R. Zitnik, A. Wang et al; Etanercept Psoriasis Study Group. 2003. Etanercept as monotherapy in patients with psoriasis. N. Engl. J. Med. 349:2014.
6. Gottlieb A.B., R.T. Matheson, N. Lowe, G.G. Krueger, S. Kang, B.S. Goffe et al. 2003. A randomized trial of etanercept as monotherapy for psoriasis. Arch. Dermatol. 139:1627.
7. Papp K.A., S. Tyring, M. Lahfa, J. Prinz, C.E. Griffiths, A.M. Nakanishi, et al; Etanercept Psoriasis Study Group. 2005. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br. J. Dermatol. 152:1304.
8. Nestorov I., R. Zitnik and T. Ludden. 2004. Population pharmacokinetic modeling of subcutaneously administered etanercept in patients with psoriasis. J. Pharmacokinet. Pharmacodyn. 31:463.
9. Zhou H. 2005. Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein. J. Clin. Pharmacol. 45:490.
10. Keystone E.C., M.H. Schiff, J.M. Kremer, S. Kafka, M. Lovy, T. DeVries et al. 2004. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 50:353.
11. Krueger G.G., R.G. Langley, A.Y. Finlay, C.E. Griffiths, J.M. Woolley, D. Lalla et al. 2005. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. Br. J. Dermatol. 153:1192.